查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1629880

全球給藥設備市場 - 2025-2033

Global Drug Delivery Devices Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2023年，全球給藥裝置市場規模達857億美元，預計2033年將達到1,365億美元，2025-2033年預測期間複合年成長率為5.9%。

藥物傳輸裝置在現代醫學中至關重要，它將藥物化合物輸送到特定的身體部位以獲得所需的治療效果。他們使用各種方法、配方和技術來最佳化藥物給藥、增強療效並儘量減少副作用。傳統方法可能會導致藥物水平波動，進而影響治療效果。新型藥物輸送系統 (NDDS) 提供控釋機制，可長時間維持治療藥物濃度。

市場動態：

驅動程式和限制

科技進步的崛起

技術進步正在改變給藥設備市場，提高給藥效率和精確度。關鍵創新包括標靶藥物傳遞系統，它將治療藥物引導至患病組織，最大限度地減少副作用並改善治療結果，特別是在腫瘤學領域。口服給藥技術也正在解決胃腸道分解和可變吸收率等挑戰。

例如，植入式藥物輸送系統（IDDS）是一種治療慢性病的新方法，提供受控和有針對性的治療介入。與傳統的口服藥物不同，IDDS 可作為內部藥物儲存庫，直接在作用部位或進入體循環提供精確的劑量。 IDDS 的一項有前景的應用是慢性疼痛管理，患者可以避免複雜的給藥方案和與口服止痛藥相關的潛在副作用。透過將鎮痛劑直接輸送到腦脊髓液中，IDDS 繞過血腦屏障，最大限度地減少全身暴露和副作用。可程式幫浦還可以控制藥物釋放，確保長時間持續緩解疼痛。

嚴格的監管要求

全球給藥設備市場面臨許多監管挑戰，包括不同的地區要求、缺乏明確的指導方針以及日本等市場的嚴格監管。這可能會導致開發時間和成本增加，特別是對於整合藥物和設備的組合產品。缺乏明確的指導方針可能會導致製造商在遵守特定標準方面感到困惑。

隨著技術的發展，監管機構更加重視軟體品質和網路安全，這增加了核准流程的複雜性。公司還必須做好準備，應對對製造品質和設備性能進行更嚴格的審查，這正成為全球監管機構的焦點。這些挑戰需要製造商和監管機構之間進行策略規劃和協作，以成功開發產品和進入市場。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 科技進步的崛起
    • 限制
      • 嚴格的監管要求
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析

第 6 章：按裝置類型

  • 注射裝置
    • 注射器
    • 自動注射器
    • 筆式注射器
    • 點滴幫浦
  • 吸入裝置
    • 霧化器
    • 乾粉吸入器 (DPI)
    • 定量吸入器 (MDI)
  • 經皮裝置
    • 經皮貼劑
    • 口服給藥裝置
    • 口腔崩解片 (ODT)
    • 口服溶膜
  • 植入式給藥裝置
    • 微型植入物
    • 藥物洗脫支架
  • 眼部給藥裝置
    • 眼藥水
    • 眼部植入物
  • 鼻腔給藥裝置
    • 鼻噴劑
    • 滴鼻劑
  • 其他

第 7 章：按申請

  • 癌症
  • 呼吸系統疾病
  • 疼痛管理
  • 神經系統疾病
  • 荷爾蒙失調
  • 其他

第 8 章：最終用戶

  • 醫院
  • 診所
  • 家庭護理設置
  • 門診手術中心 (ASC)

第 9 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 10 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 11 章：公司簡介

  • Pfizer Inc
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Johnson & Johnson
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Becton, Dickinson and Company
  • Sanofi
  • Boehringer Ingelheim
  • Merck & Co., Inc.
  • Boston Scientific Corporation
  • Teva Pharmaceuticals Industries Ltd

第 12 章：附錄

簡介目錄
Product Code: MD1826

The global drug delivery devices market reached US$ 85.7 billion in 2023 and is expected to reach US$ 136.50 billion by 2033, growing at a CAGR of 5.9% during the forecast period 2025-2033.

Drug delivery devices are crucial in modern medicine, transporting pharmaceutical compounds to specific body sites for desired therapeutic effects. They use various methods, formulations, and technologies to optimize drug administration, enhance efficacy, and minimize side effects. Traditional methods can cause fluctuations in drug levels, compromising treatment effectiveness. Novel Drug Delivery Systems (NDDS) provide controlled release mechanisms to maintain therapeutic drug concentrations over extended periods.

Market Dynamics: Drivers & Restraints

Rise in the Technological Advancements

Technological advancements are transforming the drug delivery devices market, improving medication administration efficiency and precision. Key innovations include targeted drug delivery systems, which direct therapeutic agents to diseased tissues, minimizing side effects and improving treatment outcomes, especially in oncology. Oral drug delivery technologies are also addressing challenges like gastrointestinal tract degradation and variable absorption rates.

For instance, Implantable drug delivery systems (IDDS) are a new approach to managing chronic conditions, offering a controlled and targeted therapeutic intervention. Unlike traditional oral medications, IDDS function as internal drug repositories, delivering precise doses directly at the site of action or into the systemic circulation. One promising application of IDDS is in chronic pain management, where patients can avoid complex dosing schedules and potential side effects associated with oral pain relievers. By delivering analgesic agents directly into the cerebrospinal fluid, IDDS bypasses the blood-brain barrier, minimizing systemic exposure and side effects. Programmable pumps also allow for controlled medication release, ensuring consistent pain relief for extended periods.

Stringent Regulatory Requirements

The global drug delivery devices market faces numerous regulatory challenges, including varying regional requirements, lack of clear guidelines, and stringent regulations in markets like Japan. This can lead to increased development times and costs, especially for combination products that integrate drugs and devices. The lack of clear guidelines can cause confusion among manufacturers regarding compliance with specific standards.

As technology evolves, regulators place greater emphasis on software quality and cybersecurity, adding complexity to the approval process. Companies must also be prepared for increasing scrutiny on manufacturing quality and device performance, which is becoming a focal point for regulatory bodies globally. These challenges require strategic planning and collaboration between manufacturers and regulators for successful product development and market entry.

Segment Analysis

The global drug delivery devices market is segmented based on device type, application, end user and region.

Device Type:

Injectable devices segment is expected to dominate the drug delivery devices market share

The injectable devices segment holds a major portion of the drug delivery devices market share and is expected to continue to hold a significant portion of the drug delivery devices market share during the forecast period.

Injectable devices are a key player in the global drug delivery market, driven by the increasing prevalence of chronic diseases like diabetes, cancer, and autoimmune disorders. These devices offer advantages like targeted administration, rapid absorption, and improved patient compliance. Technological advancements have led to the development of self-injectable devices and smart injectors, improving convenience and accuracy in medication delivery. The introduction of biologics and biosimilars further expands the market, as injectable systems provide precise dosing for these therapies. With rising healthcare expenditures, injectable devices are expected to become a cornerstone of modern therapeutic strategies.

For instance, in October 2024, UPM Biomedicals has launched FibGel, a natural injectable hydrogel for permanent implantable medical devices. Made from birch wood cellulose and water, FibGel is a safe, sustainable, and biocompatible alternative for medical device developers. Designed and manufactured under ISO 13485 standards in Finland, it is poised to transform soft tissue repair, orthopaedics, and regenerative medicine fields.

Application:

Cancer segment is the fastest-growing segment in drug delivery devices market share

The cancer segment is the fastest-growing segment in the drug delivery devices market share and is expected to hold the market share over the forecast period.

Cancer is driving the global drug delivery devices market, requiring advanced and targeted treatment methods. Innovative technologies like implantable pumps, transdermal patches, and nanoparticle-based carriers are being developed to improve therapeutic efficacy and minimize side effects. The integration of personalized medicine and immunotherapy in cancer care has accelerated advancements in devices delivering monoclonal antibodies, chemotherapy agents, and gene-editing solutions. These innovations aim to improve patient compliance, pharmacokinetics, and outcomes, bolstering the market's growth trajectory.

For instance, in November 2024, TriSalus Life Sciences Inc has launched the TriNav LV Infusion System and TriGuide Guiding Catheter, two advanced oncology innovations designed to optimize therapeutic delivery for liver and pancreatic tumor treatment, potentially improving patient outcomes and enhancing treatment options.

Geographical Analysis

North America is expected to hold a significant position in the drug delivery devices market share

North America holds a substantial position in the drug delivery devices market and is expected to hold most of the market share due to the novel product launches, adoption of innovative medical technologies, and the prevalence of chronic diseases like diabetes and cancer. Regulatory support from organizations like the FDA encourages innovation and expedites the approval of advanced drug delivery systems. The presence of leading pharmaceutical and biotechnology companies and substantial R&D investments contribute to the development and commercialization of cutting-edge drug delivery solutions, making North America a major driver of growth.

For instance, in December 2024, NuGen Medical Devices has launched its InsuJet needle-free insulin delivery device in Canada, generating $670,000 in revenue. Launched on November 15, the device uses a simple spring-loaded mechanism to release the drug as a fine jet stream of liquid, allowing it to penetrate the skin through a microscopic entrance. The device dispenses the drug safely and evenly in less than one-tenth of a second, with minimal pain or skin damage. The device is approved for sale in 42 countries.

Europe is growing at the fastest pace in the drug delivery devices market

Europe holds the fastest pace in the drug delivery devices market and is expected to hold most of the market share due to the significant advancements, product launches, established healthcare system, patient-centric care, and rising prevalence of chronic diseases. The European Medicines Agency (EMA) and strong pharmaceutical and biotechnology industry, along with government initiatives to boost healthcare innovation, facilitate the development and approval of innovative drug delivery solutions. This combination, along with the rising prevalence of chronic diseases, contributes to Europe's pivotal role in the global drug delivery devices market.

For instance, in November 2024, Sol-Millennium Medical Group has launched the InsuJet Needle-free Device, a needle-free insulin administration device designed to improve the quality of life for Billions of diabetic patients by eliminating discomfort associated with traditional needle-based injections.

Moreover, in July 2024, Smithers opened a new laboratory near Frankfurt, Germany, focusing on testing medical devices and pharmaceutical products. The facility, part of the Smithers Medical Device Testing Division, will offer drug delivery device testing services to clients worldwide. The 800 square meters facility will be equipped with state-of-the-art equipment and is located 12 km from Frankfurt Airport, allowing for quicker transport of samples and regular client visits. The new facility will increase testing capabilities and capacity.

Competitive Landscape

The major global players in the drug delivery devices market include Pfizer Inc, Johnson & Johnson, Novartis AG, F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Sanofi, Boehringer Ingelheim, Merck & Co., Inc., Boston Scientific Corporation, Teva Pharmaceuticals Industries Ltd and among others.

Key Developments

  • In October 2024, Researchers from the Institute of Nano Science and Technology (INST) Mohali have developed a novel drug delivery system for treating Central Nervous System Tuberculosis (CNS-TB). The system uses the nasal route to deliver anti-TB drugs directly to the brain, bypassing the blood-brain barrier (BBB) limitations. CNS-TB, a life-threatening condition, affects the brain and spinal cord, causing symptoms like headaches, fever, neck stiffness, seizures, and neurological impairments. Untreated CNS-TB can lead to severe complications.
  • In January 2024, Kindeva Drug Delivery, a global leader in drug-device combination products, has launched a new business unit to provide integrated analytical support to the pharmaceutical, biopharmaceutical, and medical device sectors. The new unit will use Kindeva's 32,000-square-foot laboratories to support inhaled, injectable, and transdermal drug delivery development programs and cGMP commercial supply. The company also has deep expertise in cGMP analytical services supporting its product development and supply partners. This expansion will further expand Kindeva's global analytical footprint.

Emerging Players

The emerging players in the drug delivery devices market include Portal Instruments, Eyenovia, Inc, Credence MedSystems and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global drug delivery devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Component & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Device Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Requirements
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Device Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 6.1.2. Market Attractiveness Index, By Device Type
  • 6.2. Injectable Devices*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Syringes
    • 6.2.4. Auto-Injectors
    • 6.2.5. Pen Injectors
    • 6.2.6. Infusion Pumps
  • 6.3. Inhalation Devices
    • 6.3.1. Nebulizers
    • 6.3.2. Dry Powder Inhalers (DPIs)
    • 6.3.3. Metered Dose Inhalers (MDIs)
  • 6.4. Transdermal Devices
    • 6.4.1. Transdermal Patches
    • 6.4.2. Oral Drug Delivery Devices
    • 6.4.3. Oral Disintegrating Tablets (ODTs)
    • 6.4.4. Oral Soluble Films
  • 6.5. Implantable Drug Delivery Devices
    • 6.5.1. Micro-Implants
    • 6.5.2. Drug-eluting Stents
  • 6.6. Ocular Drug Delivery Devices
    • 6.6.1. Eye Drops
    • 6.6.2. Ocular Implants
  • 6.7. Nasal Drug Delivery Devices
    • 6.7.1. Nasal Sprays
    • 6.7.2. Nasal Drops
  • 6.8. Others

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Cancer*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Respiratory Diseases
  • 7.4. Pain Management
  • 7.5. Neurological Disorders
  • 7.6. Hormonal Disorders
  • 7.7. Others

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Clinics
  • 8.4. Homecare Settings
  • 8.5. Ambulatory Surgical Centers (ASCs)

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Pfizer Inc*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Johnson & Johnson
  • 11.3. Novartis AG
  • 11.4. F. Hoffmann-La Roche AG
  • 11.5. Becton, Dickinson and Company
  • 11.6. Sanofi
  • 11.7. Boehringer Ingelheim
  • 11.8. Merck & Co., Inc.
  • 11.9. Boston Scientific Corporation
  • 11.10. Teva Pharmaceuticals Industries Ltd

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1 About Us and Services
  • 12.2 Contact Us